Fox Run Management L.L.C. Makes New Investment in GSK PLC Sponsored ADR $GSK

Key Points

• Fox Run Management L.L.C. has acquired a new stake in GSK PLC, purchasing 35,784 shares valued at approximately $1.39 million in the first quarter.
• GSK's recent quarterly earnings exceeded analyst expectations, reporting $1.23 earnings per share against a forecast of $1.12, alongside a revenue of $10.64 billion.
• The company announced a quarterly dividend of $0.4206 per share, representing an annualized dividend yield of 4.3% as it prepares to pay stockholders on October 9th.

Fox Run Management L.L.C. bought a new position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 35,784 shares of the pharmaceutical company's stock, valued at approximately $1,386,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its stake in GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares during the period. Costello Asset Management INC purchased a new stake in GSK in the 1st quarter worth approximately $31,000. Richardson Financial Services Inc. grew its stake in GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares during the period. Olde Wealth Management LLC purchased a new stake in GSK in the 1st quarter worth approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its stake in GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Down 0.8%

Shares of NYSE:GSK traded down $0.31 during midday trading on Monday, hitting $39.05. 2,442,386 shares of the company's stock traded hands, compared to its average volume of 5,206,852. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The company has a market cap of $79.57 billion, a PE ratio of 18.08, a P/E/G ratio of 1.71 and a beta of 0.51. The firm's fifty day moving average price is $38.50 and its two-hundred day moving average price is $37.99. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business's quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.43 EPS. On average, equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.3%. GSK's payout ratio is currently 77.78%.

Wall Street Analysts Forecast Growth

Several research firms have commented on GSK. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.